Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05141422 | Unknown status | Human Immunodeficiency Virus Infection

A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers
Sponsor:

Jiangsu H鞥R UI medicine co., Ltd.

Brief Summary:

The study is a single-centre, open-label, fixed-sequence, self-controlled clinical trial. It is planned to enroll 20 healthy adult subjects. Subjects will take SHR2150 on Day 1 and Day 21, and take efavirenz from Day 7 to Day 26.

Condition or disease

Human Immunodeficiency Virus Infection

Intervention/treatment

SHR2150 tablet、efavirenz

Phase

Phase 1

Study Type : Interventional
Estimated Enrollment : 20 participants
Masking : None (Open Label)
Primary Purpose : Basic Science
Official Title : A Single-centre, Single-arm, Open-label and Fixed-sequence Drug-drug Interaction Study to Evaluate the Effect of Efavirenz on the Pharmacokinetics of SHR2150 in Healthy Chinese Subjects
Actual Study Start Date : December 13, 2021
Estimated Primary Completion Date : January 15, 2022
Estimated Study Completion Date : January 22, 2022
Arm Intervention/treatment

Experimental: Treatment group

SHR2150+ efavirenz

Drug: SHR2150 tablet、efavirenz
Ages Eligible for Study: 18 Years to 45 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: Accepts Healthy Volunteers
Criteria
Inclusion Criteria
  • The subject can communicate well with the researcher, understand and comply with the requirements of this study, and understand and sign the informed consent;
  • Healthy subjects aged 18 ~ 45 (including the boundary value), male and female;
  • Male body weight ≥ 50 kg, female body weight ≥ 45 kg, body mass index (BMI) within the range of 18 ~ 26 kg/m2 (including the boundary value) (BMI= weight (kg)/height 2 (m2));
  • The physical examination, vital signs, laboratory examination, 12-lead electrocardiogram, abdominal B-ultrasound, and chest radiograph are normal or have no clinical significance;
  • The subjects with reproduction ability must agree to take effective contraceptive measures after signing the informed consent form and within 7 months (for female) or 4 months (for male) until the last medication.
Exclusion Criteria
  • Anyone who has suffered from any clinical serious disease such as the circulatory system, endocrine system, nervous system, digestive system, respiratory system, urogenital system, hematology, immunology, psychiatry and metabolic abnormalities, or any other disease which can affect the study results;
  • Those who have undergone surgery within 3 months before the trial, or plan to perform surgery during the study period;
  • Those whose 12-lead ECG is abnormal with clinically significant or ECG QT interval (QTcF) ≥ 450 ms (for male) or > 460 ms (for female) or < 300 ms;
  • Those who donated blood or suffered heavy blood loss (≥400 mL), received blood transfusions, or used blood products within 3 months before enrollment;
  • Have a history of allergies to drugs, food or other substances;
  • Those who have used soft drugs or hard drugs; or those with positive results in urine drug abuse screening;
  • Those who have participated in any clinical trials and have taken study drugs within 3 months before the first administration;
  • Those who have taken any medicine within 1 month before the first administration (including prescription medicines, non-prescription medicines, Chinese herbal medicines, vitamins, calcium tablets and other food supplements), especially the drugs which have any effect on CYP3A4;
  • Regular drinkers within 3 months before the test, that is, drinking more than 15 g of alcohol per day (15 g alcohol = 450 mL of beer, or 50 mL of spirits, or 150 mL of wine), and any alcohol-containing products cannot be stopped during the study;
  • Hepatitis B virus surface antigen is positive, or hepatitis C virus antibody is positive, or treponema pallidum antibody is positive, or human immunodeficiency virus antibody is positive;
  • Women with pregnancy or within lactation period.
A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers

Location Details

Please Choose a site

A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Not yet recruiting

China, Liaoning

The People's Hospital of Liaoning Province

Shenyang, Liaoning, China, 110067